1. Home
  2. MAIA vs RGS Comparison

MAIA vs RGS Comparison

Compare MAIA & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • RGS
  • Stock Information
  • Founded
  • MAIA 2018
  • RGS 1922
  • Country
  • MAIA United States
  • RGS United States
  • Employees
  • MAIA N/A
  • RGS N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • RGS Other Consumer Services
  • Sector
  • MAIA Health Care
  • RGS Consumer Discretionary
  • Exchange
  • MAIA Nasdaq
  • RGS Nasdaq
  • Market Cap
  • MAIA 46.7M
  • RGS 44.6M
  • IPO Year
  • MAIA 2022
  • RGS 1991
  • Fundamental
  • Price
  • MAIA $2.03
  • RGS $18.89
  • Analyst Decision
  • MAIA
  • RGS
  • Analyst Count
  • MAIA 0
  • RGS 0
  • Target Price
  • MAIA N/A
  • RGS N/A
  • AVG Volume (30 Days)
  • MAIA 319.8K
  • RGS 8.4K
  • Earning Date
  • MAIA 05-20-2025
  • RGS 05-13-2025
  • Dividend Yield
  • MAIA N/A
  • RGS N/A
  • EPS Growth
  • MAIA N/A
  • RGS N/A
  • EPS
  • MAIA N/A
  • RGS 40.46
  • Revenue
  • MAIA N/A
  • RGS $191,336,000.00
  • Revenue This Year
  • MAIA N/A
  • RGS N/A
  • Revenue Next Year
  • MAIA N/A
  • RGS N/A
  • P/E Ratio
  • MAIA N/A
  • RGS $0.51
  • Revenue Growth
  • MAIA N/A
  • RGS N/A
  • 52 Week Low
  • MAIA $1.40
  • RGS $3.87
  • 52 Week High
  • MAIA $5.99
  • RGS $35.50
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 53.91
  • RGS 55.03
  • Support Level
  • MAIA $1.80
  • RGS $17.50
  • Resistance Level
  • MAIA $2.18
  • RGS $19.50
  • Average True Range (ATR)
  • MAIA 0.30
  • RGS 0.99
  • MACD
  • MAIA -0.01
  • RGS 0.17
  • Stochastic Oscillator
  • MAIA 30.29
  • RGS 84.54

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About RGS Regis Corporation

Regis Corp owns, franchises, and operates beauty salons throughout North America and the United Kingdom. The company's locations provide salon products and services to the mass market, including haircutting, styling, and hair coloring. The vast majority of Regis' salons are in strip malls, shopping centers, and Wal-Mart stores in North America and serve price-conscious customers. The company derives the majority of its revenue from these locations. The sale of products also contributes a relatively significant percentage of total sales. Regis also operates a smaller portfolio of premium salons across North America and the U.K. The company's majority brands include SmartStyle, Cost Cutters, and Supercuts.

Share on Social Networks: